



Menstrual Cycle Effects on the Dexamethasone 
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In t roduc t ion  
Patients with major depressive disorder (MDD) 
fiequently exhibit dysregulation of the hypoth- 
alamo-pituitary-adrenal (HPA) axis reflected in 
elevated basal cortisol levels as well as resis- 
tance to feedback inhibition, which is typically 
manifested by resistance to suppression by dex- 
amethasone (Carroll et al 1981; Stokes and Sikes 
1988). Alterations in and interactions between 
the HPA and hypothalamo-pituitary-gonadal 
(HPG) axes in MDD have also been documented 
(Rubin and Poland 1984; McEwen 1987). Sys- 
tematic fluctuations of gonadal steroid levels 
through the menstrual cycle have been well de- 
scribed (Yen 1980), with maximal estrogen ac- 
tivity in the periovulatory phase and maximal 
progesterone activity in the early to mid-luteal 
phase. In view of the interactions between the 
HPG and HPA axes, the relationship between 
premenstrual syndrome and mood disorders 
(Endicott et al 1985; Rubinow et al 1985; Mor- 
tola et al 1989; Graze et al 1990), and the sys- 
tematic menstrual oscillations in gonadal steroid 
activity, it would be important to evaluate pos- 
sible menstrual effects on HPA function. Early 
studies in this regard have failed to find differ- 
ences in cortisol secretory parameters between 
the follicular and luteal phase (Haskett et al 1984; 
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Mortola et al 1989). To further study possible 
menstrual changes in the HPA axis, we con- 
ducted serial dexarnethasone suppression tests 
(DSTs) through one complete menstrual cycle 
in 25 inpatients with MDD. 
M e t h o d s  
The sample consisted of 25 hospitalized men- 
struating women with a Schedule for Affective 
Disorders and Schizophrenia/Research Diag- 
nostic Criteria (SADS/RDC) diagnosis of MDD 
(Endicott and Slaitzer 1978; Spitzer et al 1978). 
Subjects who met the following inclusion/ 
exclusion criteria were retrospectively identified 
from the University of Michigan Depression 
program dataset collected over 5 years: (1) all 
subjects had one complete, carefully docu- 
mented, 4-week menstrual cycle during which 
they were medication free (n = 14) or had no 
change of antidepressant medication (n = 1 I); 
and (2) all subjects had weekly valid I mg DSTs 
(Carroll et al 1981) through the menstrual cycle. 
Menstrual cycle status was ascertained weekly 
by a research nurse based on patient report of 
onset of menses. Twenty five patients fulfilling 
these criteria were retrospectively identified from 
among 140 hospitalized menstruating women 
with MDD. Subjects ranged in age from 19 to 
45 years, mean --- SD age 34 -+ 7. Cortisol 
was assayed by Murphy's competitive protein 
binding method (Murphy 1967). Patients were 
also rated weekly on the Haafilton Rating Scale 
for Depression (HRSD~ (Hamilton 1960). 
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Five weekly DSTs were conducted in which 
week 0 corresponded to week of menses, week 
I to the follicular phase, week 2 to the perio- 
vulatory phase, week 3 to the luteal phase, and 
week 4 to menses. Maximal postdexamethasone 
cortisol levels at these five timepoints were com- 
pared by a repeated measures analysis of vari- 
ance (ANOVA). 
Resul ts  
We found that the maximal postdexamethasone 
cortisol levels were lowest at week 0 (menses- 1), 
with a mean of 3.84 ~g/dl, rose to 4.94 ttg/dl at 
week 1 (follicular), reached a peak of 7.61 ttg/dl 
at week 2 (periovulatory), declined marginally to 
6.76 ttg/dl at week 3 (luteal) before declining to 
5.00 ttg/dl at week 4 (menses-2). As illustrated 
in Figure 1, these differences were highly signif- 
icant (F = 9.8; df = 4,24;p < 0.001). Scheffe 
F-tests showed the following group differences 
to be significant (p < 0.05): menses-I versus 
ovulatory; menses-1 versus luteal; follicular ver- 
sus ovulatory; ovulatory versus menses-2; other 
comparisons showed no significant group differ- 
enccs. The drug-free group (n = 14) and the group 
of patients on a constant dose of antidepressant 
(n = 11) showed the same pattern (Table 1). 
These findings could not be explained by changes 
in severity of depression, weight, or olher known 
sources of variance in HPA function. In fact, the 
HRSD scores showed an inverse pattern to post- 
dexamcthason¢ cortisol levels titrough the men- 
stmal cycle (see Fig. I), with a significant men- 
strual increase in the severity of depression (F  = 
6.3; df = 4,24;p < 0.01). Again, both the drag- 
free and constant-medication groups showed this 
pattern, although mean 17-item total Hamilton 
scores were lower i~ the medicated group (Table 
1). 
In terms of categorization as DST suppres- 
sors or nonsuppressors (defined by a cutoff of 
5 Itg/di), 19 patients (10 suppressors and 9 non- 
suppressors) did not change through the men- 
strual cycle. The remaining 6 patients were DST 
nonsuppressors only during the periovulatory 
and/or luteal weeks, but suppressed normally at 
other timepoints. 
D i scus s ion  
The pattern of menstrual changes in postdexa- 
methasone cortisol levels noted in our study dif- 
fer from the findings of Haskett et al (1984). 
Haskett et al, evaluating premenstrual syndrome 
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Figure 1. Maxhnal post, dexa- 
methasone cortisol and HRSD 
through the mcnsmml cycle. 
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Table 1. Menstrual Changes in Maximal Postdexamethasone Cortisol and Hamilton Depression Ratings in 
Drug-free Patients and Patients on Constant Medication 
Menses-I  Follicular Ovulatory Luteal Menses-2 Significance (ANOVA} 
Drug-free 
(n  = 14) 
Post-dex cortisol 4 .2  _+ 3.2 
17-item H R S D  
total scores 20 _+ 6 
Constant 
medication 
(n = I I )  
Post-dex cortisol 3 4  ___ 3 .0  
17-1tern H R S D  
total scores 15 __ 6 
5.3 _ 4 .0  8 .6  ± 6 .0  6.7 + 4 .7  5.7 ~ 3.7 
18 ___ 6 18 - 5 18 -+ 4 21 _ 8 
4.5 -*- 4.5 6.3 - 5.8 £.8 _ 5.0 4 .0  ± 3.7 
13 ~ 7 13 _+ 7 13 - 7 1 6 _  8 
F = 6 . 1 ; d r  = 4 , 1 3 ; p  < 0.01 
F = 2 . 9 ; d r  = 4 , 1 3 ; p  < 0.05 
F = 4.5; d f  = 4 , 1 0 ; p  < 0.05 
F = 3.9; d f  = 4 , 1 0 ; p  < 0.05 
All values expressed as mean - stand~d deviation 
sion, performed a l-mg DST on days 10 and 
26 of a 4-week menstrual cycle in 38 women 
with well-defined premenstrual syndrome. They 
found no differences in rates of nonsuppression 
or urinary-free cortisol levels between these ti- 
mepoints. In the present study, whereas there 
were significant menstrual changes in postdex- 
amethasone cortisol levels, there were no ap- 
parent differences between day 10 (rising) and 
day 26 (falling). However, the findings are con- 
sistent with reports that plasma ACTH ievels 
peak around ovulation and are lowest during 
menses (Gennazini et al 1975; Bums 1975). They 
are also consistent with reports that plasma ~ ta -  
endorphin levels follow a similar pattern, wifi, 
rising levels through the follicular phase to a 
periov-ulatory peak and declining levels h~ough 
the luteal phase (Wehrenberg et al 1982; Ham- 
ilton and Gallant 1988). Collectively, these find- 
ings would sugges*, thvt proopiomelanocortin 
(POMC), the precursor molecule of both ACTH 
and beta-endorphin (Roberts and Herbert 1977) 
activity, may be increased in the periovulatory 
phase and decreased during menstruation. The 
findings of this study further suggest that phase 
of menstrual cycle is an important variable in 
the interpretation of results of the DST. It re- 
mains to be seen if menstrual fluctuations in 
I-IPA axis function occur in all women or are 
limited to patients with MDD. 
Menstrual fluctuations in the severity of 
depression observed in this study are co~istent 
with reports of a premenstrual exacerbation of 
depressive symptomatology (Rubinow et al 1985) 
and support the relations~p between menstrual 
mood changes and major depression tWetzel et 
al 1975; Endicott et al 1981; Halbreich and En- 
dicott 1985; Graze et al 1990). 
Findings c Y our study are l ~ t e d  by the ret- 
rospective design and identification of mens~a l  
cycle phase on the basis of patient report of onset 
of menses. Gonadal hormone levels would have 
provided a more reliable index of the phase of 
menstrual cycle. Similarly, dexamethasone lev- 
els would nave permitted a more comprehensive 
evaluation of the DST response; these were not 
obtained, however, as the subjects were selected 
retrospectively ~om a datab~,~e of patients in 
the early 1980s. Finally, our inclusion/exclusion 
criteria may have biased the patient sample by 
including more treatment-refractory patients 
(particularly in the constant-medication group). 
As a consequence, our results must be consid- 
ered preliminary. 
Menstrual changes in DST cortisol levels the- 
oretically may stem from menstrual fluctuations 
in basal HPA activity or central neurotransmit- 
ters (Cardona et al 1990), gonadal steroid mod- 
ulation of central neurotransmitters or steroid 
receptors at hypothalamic or pituitary levels 
(McEwen et al 1984), alteration of adrenal cor- 
ticosteroid metabolism, or interference with cor- 
488 BIOL PSYCHIATRY 
1990;28:485-488 
Brief Reports 
tisol assay. Possible mechanisms underlying 
menstrual fluctuations in HPA activity and their 
relationship to mood and other psychobiological 
changes through the menstrual cycle warrant 
further exploration. 
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